EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
This week:
Partnerships
Numinus partners with PharmAla Biotech for LaNeo MDMA supply in clinical trial
Psychedelic Medicine
Mar 26, 2024
Geographic expansion
Partnerships
Optimi Health partners with Tel Aviv University for MDMA supply; expands into Israeli psychedelics market
Psychedelic Medicine
Mar 26, 2024
Funding
Gilgamesh Pharmaceuticals receives USD 14 million grant to develop GM-3009 compound
Psychedelic Medicine
Mar 14, 2024
FDA approval
Cybin receives FDA breakthrough designation for CYB003 program
Psychedelic Medicine
Mar 13, 2024
Funding
Cybin announces USD 150 million private placement to advance CYB003 into Phase III clinical trials
Psychedelic Medicine
Mar 13, 2024
FDA approval
MindMed receives FDA breakthrough designation for MM120 program
Psychedelic Medicine
Mar 7, 2024
Funding
MindMed secures USD 175 million via underwritten offering and private placement
Psychedelic Medicine
Mar 7, 2024
Product updates
Clearmind Medicine files three international patents to expand intellectual property portfolio
Psychedelic Medicine
Feb 20, 2024
Funding
Optimi Health to raise CAD 1.5 million in private placement funding for commercialization efforts
Psychedelic Medicine
Feb 8, 2024
Management news
Funding
MAPS renames to Lykos Therapeutics; raises USD 100 million in Series A funding
Psychedelic Medicine
Feb 5, 2024
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.